Bloomberg Law®, an integrated legal research and business intelligence solution, combines trusted news and analysis with cutting-edge technology to provide legal professionals tools to be...
By Natasha Dhillon
The Supreme Court's recent Myriad decision is just the latest in a long string of “failure[s] in judicial lawmaking” when it comes to patent eligibility, former Chief Judge of the U.S. Court of Appeals for the Federal Circuit Paul R. Michel said June 17.
Michel, speaking at a Bloomberg Law sponsored webinar, titled “Interpreting Myriad: Gene Patenting and Other Inventions at Risk,” criticized the high court for failing to provide guidance and suggested that Congress, and not the courts, should be leading the charge on issues of patent reform.
Another speaker, Erika H. Arner, a partner at Finnegan, Henderson, Farabow, Garrett, & Dunner, Reston, VA, argued that if Myriad provides little guidance it is because the Supreme Court placed too much focus on defining Section 101 of the Patent Act, 35 U.S.C. § 101, and failed to consider the entire patent statutory scheme and settled Patent and Trademark Office practice.
The final speaker, Thomas G. Saunders, a partner at Wilmer Cutler Pickering Hale and Dorr, Washington D.C., also criticized Myriad for offering little reassurance that its impact will be limited to human DNA or composition matter claims.
The panelists seemed to agree that this brings up the question of how to define “naturally occurring,” but were also concerned that the court was creating different eligibility rules depending on the type of technology without considering future technology.
Arner also thought the court was asking Section 101 “to do too much.” She noted that Section 101 is short and broad and is supposed to be read in conjunction with the other subsections, such as Sections 102, 103, and 112, on novelty, obviousness, and written description respectively. However, she stated that the court has become fixated on interpreting and defining Section 101 without considering the other subsections, which has resulted in moving boundaries that are difficult to follow.
Michel, commenting on the court's focus on Section 101, was concerned that a Section 101 discussion would now have to be a part of every patent eligibility claim, an idea he found to be “totally backwards.” With this ruling, he said the court “risks inconsistent judgment making” where “no one can know what is patent eligible.”
Focusing on Myriad as the sixth in a line of patent cases starting in the 1970's, he thought these six cases represented a “failure in judicial lawmaking.”
He found Myriad to be another example of the Supreme Court failing to provide adequate guidance, and he said it was an example of “broad judicial activism.”
He criticized the court's reasoning for being based on policy arguments and assumptions rather than the statutory language and a detailed factual record. Pointing to Europe as a good example of how to deal with patent issues, he indicated that these questions should be answered by the legislature, and said he was ready to turn over patent issues to Congress.
While Arner said it was “nice to see that the court understood the potential consequences,” she noted that “it's hard to think about method claims without thinking about Mayo [Collaborative Services v. Prometheus Laboratories Inc., 132 S. Ct. 1289, 101 U.S.P.Q.2d 1961, (2012) (55 PTD, 3/22/12)].”
Saunders agreed saying, the “carve-out does not give much comfort in light of Mayo.” While the court tried to leave a void, the panelists did not seem optimistic that it exists. Rather they thought the void maybe filled with dicta from Mayo.
For instance, biotech industries which have a key enzyme in the fuelling process may respond with a delay in seeking patent protection that we haven't seen before, he said. Saunders said these companies will be taking a second look at trade secret protections and pursuing method claims, since this ruling indicates that it will be harder going forward to achieve a composition of matter claim.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)